Advertisement

Investigational New Drugs

, Volume 32, Issue 1, pp 75–86 | Cite as

Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin

  • Zhao Hui Li
  • Qian Zhang
  • Hai Bin Wang
  • Ya Nan Zhang
  • Ding Ding
  • Li Qiang Pan
  • David Miao
  • Shi Xu
  • Chen Zhang
  • Pei Hua Luo
  • Hua NaranmanduraEmail author
  • Shu Qing ChenEmail author
PRECLINICAL STUDIES

Summary

Utilization of antibodies to deliver highly potent cytotoxic agents to corresponding antigen-overexpressed tumor cells is a clinically validated therapeutic strategy. Ofatumumab (OFA, trade name Arzerra) is a fully human CD20-specific antibody that is active against CD20-positive B-cell lymphoma/chronic lymphocytic leukemia cells. In order to further enhance the anticancer effect of OFA, anti-CD20 OFA has been conjugated with highly cytotoxic monomethyl auristatin E (MMAE) through a cathepsin-B-cleavable valine-citrulline (vc) dipeptide linkage to form OFA-vcMMAE and the anti-tumor activity of OFA-vcMMAE against CD20-positive B lymphoma cells are then evaluated in vitro and in vivo. As a result, conjugation of OFA with MMAE has kept the initial effector functional activities of OFA such as binding affinity, complement-dependent cytotoxicity (CDC) as well as antibody-dependent cell-mediated cytotoxicity (ADCC). In addition, the conjugation of MMAE significantly improved the cytotoxic activity of OFA against CD20-positive cells (i.e., Raji, Daudi and WIL2-S cells) but not against CD20-negative K562 cells. On the other hand, OFA-vcMMAE was modulated from the CD20-positive cell surface and then entered the lysosomes by receptor-mediated endocytosis, underwent proteolytic degradation and released active drug MMAE to induce apoptotic cell death through a caspase-3-like protease-dependent pathway. Surprisingly, OFA-vcMMAE completely inhibited the growth of CD20-positive Daudi and Ramos lymphoma xenografts in vivo, and exhibited greater anti-tumor activity than unconjugated OFA, suggesting that the anti-tumor activity of anti-CD20 antibody can be enhanced by conjugation with MMAE. In the near future, this new approach might be used as a clinical treatment of CD20-positive B lymphoid malignancies.

Keywords

Ofatumumab MMAE Conjugate CD20 Targeted therapy 

Abbreviations

Ab

Antibody

ADC

Antibody-drug conjugate

ADCC

Antibody-dependent cell-mediated cytotoxicity

CCK-8

Cell Counting Kit-8

CDC

Complement-dependent cytotoxicity

MAb

Monoclonal antibody

MFI

Geometric mean fluorescence intensity ratio

MMAE

Monomethyl auristatin E

OFA

Ofatumumab

PARP

Poly (ADP-ribose) polymerase

PI

Propidium iodide

vc

Valine-citrulline

Notes

Acknowledgments

The authors wish to acknowledge the National Natural Science Foundation of China (No. 81001477, 81274138), the Science and Technology Department of Zhejiang Province (No. 2009C13034), Zhejiang Provincial Natural Science Foundation of China (No.R2110231), the Key Science and Technology Innovation Team of Zhejiang Province (No. 2010R50047).

Competing interests

The authors declare that there are no conflicts of interest.

References

  1. 1.
    Sioud M, Mobergslien A (2012) Selective killing of cancer cells by peptide-targeted delivery of an anti-microbial peptide. Biochem Pharmacol 84(9):1123–1132. doi: 10.1016/j.bcp.2012.08.002 CrossRefPubMedGoogle Scholar
  2. 2.
    Goldmacher VS, Kovtun YV (2011) Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv 2(3):397–416CrossRefPubMedGoogle Scholar
  3. 3.
    Stack GD, Walsh JJ (2012) Optimising the delivery of tubulin targeting agents through antibody conjugation. Pharm Res 29(11):2972–2984. doi: 10.1007/s11095-012-0810-9 CrossRefPubMedGoogle Scholar
  4. 4.
    Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA (2012) Antibody-drug conjugates - a perfect synergy. Expert Opin Biol Ther 12(9):1191–1206. doi: 10.1517/14712598.2012.693473 CrossRefPubMedGoogle Scholar
  5. 5.
    Tedder TF, Engel P (1994) CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 15(9):450–454. doi: 10.1016/0167-5699(94)90276-3 CrossRefPubMedGoogle Scholar
  6. 6.
    Maloney DG (2005) Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 23(26):6421–6428. doi: 10.1200/JCO.2005.06.004 CrossRefPubMedGoogle Scholar
  7. 7.
    McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8):2825–2833PubMedGoogle Scholar
  8. 8.
    Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, Valerius T, van de Winkel JG, Glennie MJ (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104(6):1793–1800. doi: 10.1182/blood-2004-01-0039 CrossRefPubMedGoogle Scholar
  9. 9.
    Cheson BD (2010) Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol 28(21):3525–3530. doi: 10.1200/JCO.2010.27.9836 CrossRefPubMedGoogle Scholar
  10. 10.
    Zhang B (2009) Ofatumumab. MAbs 1(4):326–331PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Veliz M, Pinilla-Ibarz J (2011) Role of ofatumumab in treatment of chronic lymphocytic leukemia. J Blood Med 2:71–77. doi: 10.2147/JBM.S13063 PubMedCentralPubMedGoogle Scholar
  12. 12.
    Dyer MJ (2012) Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. Ther Adv Hematol 3(4):199–207. doi: 10.1177/2040620712445329 PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, Handley FG, Ihle NC, Senter PD, Alley SC (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 16(5):1282–1290. doi: 10.1021/bc050201y PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102(4):1458–1465. doi: 10.1182/blood-2003-01-0039 CrossRefPubMedGoogle Scholar
  15. 15.
    Han KY, Yang D, Chang EJ, Lee Y, Huang H, Sung SH, Lee ZH, Kim YC, Kim HH (2007) Inhibition of osteoclast differentiation and bone resorption by sauchinone. Biochem Pharmacol 74(6):911–923. doi: 10.1016/j.bcp.2007.06.044 CrossRefPubMedGoogle Scholar
  16. 16.
    Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer DL, Doronina SO, Siegall CB, Francisco JA, Senter PD, Wahl AF (2004) Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 10(23):7842–7851. doi: 10.1158/1078-0432.CCR-04-1028 CrossRefPubMedGoogle Scholar
  17. 17.
    Beekman JM, van der Poel CE, van der Linden JA, van den Berg DL, van den Berghe PV, van de Winkel JG, Leusen JH (2008) Filamin A stabilizes Fc gamma RI surface expression and prevents its lysosomal routing. J Immunol 180(6):3938–3945CrossRefPubMedGoogle Scholar
  18. 18.
    Lv M, Lin Z, Qiao C, Gen S, Lang X, Li Y, Feng J, Shen B (2010) Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity. Cancer Lett 294(1):66–73. doi: 10.1016/j.canlet.2010.01.023 CrossRefPubMedGoogle Scholar
  19. 19.
    Naranmandura H, Chen X, Tanaka M, Wang WW, Rehman K, Xu S, Chen Z, Chen SQ, Suzuki N (2012) Release of apoptotic cytochrome C from mitochondria by dimethylarsinous acid occurs through interaction with voltage-dependent anion channel in vitro. Toxicol Sci 128(1):137–146. doi: 10.1093/toxsci/kfs154 CrossRefPubMedGoogle Scholar
  20. 20.
    Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10(20):7063–7070. doi: 10.1158/1078-0432.CCR-04-0789 CrossRefPubMedGoogle Scholar
  21. 21.
    Sievers EL, Senter PD (2013) Antibody-drug conjugates in cancer therapy. Annu Rev Med 64:15–29. doi: 10.1146/annurev-med-050311-201823 CrossRefPubMedGoogle Scholar
  22. 22.
    Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, Payne G, Steeves R, Whiteman KR, Widdison W, Xie H, Singh R, Chari RV, Lambert JM, Lutz RJ (2011) Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 22(4):717–727. doi: 10.1021/bc100480a CrossRefPubMedGoogle Scholar
  23. 23.
    Braslawsky GR, Kadow K, Knipe J, McGoff K, Edson M, Kaneko T, Greenfield RS (1991) Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity. Cancer Immunol Immunother 33(6):367–374CrossRefPubMedGoogle Scholar
  24. 24.
    Goulet AC, Goldmacher VS, Lambert JM, Baron C, Roy DC, Kouassi E (1997) Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization. Blood 90(6):2364–2375PubMedGoogle Scholar
  25. 25.
    Nightingale G (2011) Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. Ann Pharmacother 45(10):1248–1255. doi: 10.1345/aph.1P780 CrossRefPubMedGoogle Scholar
  26. 26.
    Lin TS (2010) Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics Pers Med 3:51–59PubMedCentralPubMedGoogle Scholar
  27. 27.
    Michel RB, Mattes MJ (2002) Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res 8(8):2701–2713PubMedGoogle Scholar
  28. 28.
    Pettit GR (1997) The dolastatins. Fortschr Chem Org Naturst 70:1–79PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Zhao Hui Li
    • 1
  • Qian Zhang
    • 1
  • Hai Bin Wang
    • 2
  • Ya Nan Zhang
    • 1
  • Ding Ding
    • 1
  • Li Qiang Pan
    • 1
  • David Miao
    • 3
  • Shi Xu
    • 1
  • Chen Zhang
    • 1
  • Pei Hua Luo
    • 1
  • Hua Naranmandura
    • 1
    Email author
  • Shu Qing Chen
    • 1
    Email author
  1. 1.Department of Pharmacology, Toxicology and Biochemical Pharmaceutics, College of Pharmaceutical SciencesZhejiang UniversityHangzhouChina
  2. 2.Biotechnology R&D DepartmentZhejiang Hisun Pharmaceutical Co. Ltd.TaizhouChina
  3. 3.Concortis Biosystems, Corp.San DiegoUSA

Personalised recommendations